News Medical

PD-1 helps guide immune memory cells to the skin early during infection

Weill Cornell Medicine researchers have discovered that PD-1—a molecule best known for putting the brakes on immune cells—also plays a critical role in helping T cells become long-term immune ...
Managed Healthcare Executive

Regeneron’s Libtayo FDA Approved as First Immunotherapy to Reduce Recurrence of High-Risk Squamous Cell Skin Cancer

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...
ascopubs.org

Combined PD-L1 expression and PD-1+ CD8 T cells to predict immunotherapy outcomes in esophageal squamous cell carcinoma.

Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial. This is an ASCO Meeting ...

MIT researchers build universal cancer-fighting immune cells

In a breakthrough cancer therapy development, scientists at MIT and Harvard Medical School created a new way of designing ...
The American Journal of Managed Care

CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

Next-generation CAR T cells could expand solid cancer treatment options

T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and ...

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for ...